CIMG, through its subsidiary DZR, signed an agreement to acquire 100% of Daren Technology for approximately $40M in stock. The transaction features a highly structured Phased Payment consideration (6%, 14%, 28%, and 52%) released over 3.5 years. This earn-out structure is strictly tied to Daren achieving aggressive audited revenue targets, starting at $29M in 2026 and scaling to $257M by September 2029. This structure ensures alignment between the acquisition cost and the realized growth of the target's biopharmaceutical activities.

The transaction values DAREN TECHNOLOGY at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.